Evaluation of antibody titers, specific hematological parameters, and clinical manifestations correlated of SARS-CoV-2 infection Among symptomatic COVID-19 patients at the Brak isolation center in Libya.
DOI:
https://doi.org/10.65405/n2svym44Keywords:
SARS-COV-2, COVID-19, Antibody titers, Clinical manifestations , Hematological parametersAbstract
Coronaviruses are a group of viruses that make mammals and birds sick. Some members of this group can infect people, and the new coronavirus (SARS-CoV-2) is a new strain of this group. It is the cause of the current worldwide pandemic, and it has never been found in people before. The virus can be passed from animals to people. This study was conducted to investigate the disease's distribution among patients and to evaluate antibody titers, considering the limited research on this virus in Libya despite its prevalent occurrence in various regions. Results: An analysis of 25 confirmed cases showed that men (18 cases; 72%) were more likely to get infected than women (7 cases; 28%).
The results showed that the risk of getting an infection went up with age, especially for people between the ages of 50 and 59. The most common clinical sign was fever, which was present in 23 cases (92%). Additionally, individuals with chronic conditions, including diabetes mellitus and hypertension, exhibited a heightened susceptibility to infection (41.9%). Pearson's correlation analysis indicated a positive association between CRP and D-dimer (R = 0.5, P = 0.06), although it lacked statistical significance. The lymphocyte count showed a negative correlation with CRP (R = -0.5, P = 0.3) and D-dimer (R = -0.5, P = 0.1), but neither of these correlations was statistically significant.
Downloads
References
1. Shereena.M. A. Khana, S, Kazmie, A., Bashira N, and Siddique R.(2020).COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. Journal of Advanced Research. 24 (2020): 91-98.
2. Cascella M. Rajnik M. Cuomo A. Dulebohn S and Di Napoli R.(2020). Features, Evaluation, and Treatment of Coronavirus (COVID-19). 20. Oct. 2020.https://www.nebi.nlm.nih.gov/books/NBK554776/.
3. Boopathia ,S. Pomab, A. B. and Kolandsivel, P. (2020), Novel 2019 Coronavirus Structure, Mechanism of Action, Antiviral drug promises and rule out against its treatment.
4. CHEN, N. ZHOU, M.. DONG. X.. QU, J., GONG, F. HAN, Y.. QIU, Y.. WANG. J., LIU, Y. & WEI. Y. 2020. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet, 395, 507-513.
5. PENG, X. XU, X.. LI. Y.. CHENG. L.., ZHOU. X. & REN, B. 2020. Transmission routes of 2019-nCoV and controls in dental practice. International Journal of Oral Science, 12, 1-6.
6. Hassan S. Sheikh F N, Jamal S, Ezeh J K and Akhtar A. (2020) Coronavirus (COVID-19): A Review of Clinical Features, Diagnosis, and Treatment. Cureus 12(3): e7355.
7. Wu. Y., Guo, C., Tang. L.., Hong, Z.. Zhou. J.. Dong. X., Yin. H.. Xiao. Q, Tung, Y.. Qu X..Kuang. L.., Fang. L.. Mishra, N., Lu, J., Shan, H.. Jiang, G. and Huang. X (2020). Prolonged presence of SARS-CoV-2 viral RNA in faecal samples https://doi.org/10.1016/S2468-1253(20)30083-2.
8. Pascarella, G, Strumia, A, Piliego, C, Bruno .F. Bueno, R. Costa F. Scarlata, S and Agrò, F E. (2020). COVID-19 diagnosis and management: a comprehensive review. Journal of Internal Medicine 288(2):1-16.
9. Gennaro, F. D. Pizzol, D. ,Marotta, C., Antunes ,M. Racalbuto, V., Veronese. N and Smith, L.(2020). Coronavirus Diseases (COVID-19) Current Status and Future Perspectives: A Narrative Review. International Journal of Environmental Research and Public Health. 17(8): 2690.
10. Zhou. F., Yu. T., Du, R. Fan, G, Liu, Y., Liu, Z., Xiang, J, Wang. Y., Song, B.. Gu. X. Guan, L.., Wei. Y. Li. H., Wu. X.. Xu, J., Tu. S., Zhang, Y.. Chen, H. and Cao. B (2020). Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 395(10229): 1054-1062.
11. PANG. J. WANG, M. X.. ANG, I. Y. H., TAN, S. H. X., LEWIS, R. F., CHEN, J. 1-P... GUTIERREZ, R. A., GWEE, S. X. W., CHUA, P. E, Y. & YANG. Q. 2020. Potential rapid diagnostics, vaccine and therapeutics for 2019 novel coronavirus (2019 nCoV) systematic review. Journal of clinical medicine. 9, 623.
12. zhao-Hua Zhou, Sai Dharmarajan, MariLehtimaki, Susan L. Kirshner, Steven Koziowski, (2021). Title: Early Antibody Responses Associated with Survival in COVID19 Patients Retrieved from https://doi.org/10.1101/2021.02.21.21252168.
13. Sahin AR. Erdogan A, MutluAgaoplu P. Dineri Y. Cakirei AY. Senel ME, Okyay. R. A.. Tasdogan, A. M.( 2020), 2019 Novel Coronavirus (COVID-19) Outbreak: A Review of the Current Literature. EJMO:4(1):1-7.
14. DAS. S. K. 2020. The Pathophysiology, Diagnosis and Treatment of Corona Virus Disease 2019 (COVID-19). Indian Journal of Clinical Biochemistry, 1-12. DESAI, A. N. 2020. Discussing the ABCs of Health Security-Antibiotic Resistance, Biothreats, and Coronavirus. Jama, 323, 912-914.
15. Tang N. Li D. Wang X. and Sun Z. (2020). Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Journal of Thrombosis and Haemostasis. 18(4):844-7.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Comprehensive Journal of Science

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.








